Ligand Competitors

Stocks . USA . 
Stock . Ligand Pharmaceuticals Incorporated
LGND Stock  USD 111.89  0.81  0.73%   
Ligand Pharmaceuticals competes with Passage Bio, Oric Pharmaceuticals, Lyell Immunopharma, Design Therapeutics, and Ascendis Pharma; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Ligand Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Ligand Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Ligand Pharmaceuticals Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Ligand Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
108.99112.12115.25
Details
Intrinsic
Valuation
LowRealHigh
100.70120.26123.39
Details
Naive
Forecast
LowNextHigh
113.85116.98120.11
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
103.22114.35125.47
Details

Ligand Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Ligand Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Ligand and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Ligand Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
VRDN
+ 0.8
LYEL
AKRO
+ 0.77
LYEL
APLS
+ 0.75
ASND
VRDN
+ 0.73
AKRO
APLS
+ 0.67
PASG
BPMC
+ 0.63
ORIC
  
High negative correlations   
ASND
- 0.63
LYEL
APLS
- 0.43
LYEL
ASND
- 0.36
ORIC
VRDN
- 0.35
ASND
VRDN
- 0.33
APLS
AKRO
- 0.3
ASND

Risk-Adjusted Indicators

There is a big difference between Ligand Stock performing well and Ligand Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Ligand Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PASG  7.33  0.69  0.08 (1.75) 7.04 
(10.15)
 20.97 
(11.88)
 84.39 
ORIC  3.53  0.26  0.05 (12.43) 4.39 
(3.67)
 8.04 
(6.91)
 22.87 
LYEL  4.71 (0.89) 0.00  1.97  0.00 
 0.00 
 11.63 
(10.68)
 36.92 
DSGN  4.38 (0.03) 0.00 (0.01) 6.27 
(4.68)
 8.72 
(11.01)
 33.11 
ASND  1.68  0.00 (0.01) 0.03  1.86 
(1.94)
 3.56 
(3.13)
 9.74 
APLS  2.59  0.18  0.04  0.20  3.79 
(2.79)
 4.63 
(4.71)
 27.73 
BGNE  1.83 (0.33) 0.00  45.28  0.00 
 0.00 
 3.46 
(4.87)
 17.00 
AKRO  2.70 (0.22) 0.00 (0.40) 0.00 
 0.00 
 5.23 
(5.05)
 16.66 
BPMC  2.14  0.42  0.16  0.52  2.19 
(2.42)
 5.87 
(3.53)
 19.12 
VRDN  2.91 (0.42) 0.00 (0.30) 0.00 
 0.00 
 4.19 
(6.93)
 29.75 
All Fundamental Data

Ligand Pharmaceuticals Competitive Analysis

The better you understand Ligand Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Ligand Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Ligand Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LGND PASG ORIC LYEL DSGN ASND APLS BGNE AKRO BPMC
 0.73 
 111.89 
Ligand
 1.69 
 0.60 
Passage
 4.58 
 9.58 
Oric
 3.57 
 0.58 
Lyell
 6.75 
 5.06 
Design
 2.65 
 128.13 
Ascendis
 0.71 
 29.94 
Apellis
 0.39 
 184.71 
BGNE
 4.71 
 25.14 
Akero
 5.87 
 110.05 
Blueprint
Market Volatility
(90 Days Market Risk)
Very steady
Out of control
Slightly risky
Out of control
Risky
Very steady
Not too volatile
Very steady
Not too volatile
Very steady
Market Performance
(90 Days Performance)
Insignificant
Insignificant
Insignificant
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
OK
Odds of Financial Distress
(Probability Of Bankruptcy)
Very Low
High
Low
High
Low
Below Average
Low
Dangerous
Low
Below Average
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Strong Sell
Current Ratio
1.45
9.23
18.72
13.26
48.96
9.66
7.57
4.54
6.9
6.0
Net Asset
787.22 M
150.54 M
252.01 M
750.03 M
289.64 M
825.59 M
788.73 M
5.81 B
580.27 M
1.05 B
Profit Margin
0.3
N/A
N/A
N/A
N/A
-1.54
-0.35
-0.25
N/A
-0.29
EBITDA
101.73 M
(98.34 M)
(109.75 M)
(226.76 M)
(66.33 M)
(411.17 M)
(495.21 M)
(1.12 B)
(148.63 M)
(470.36 M)
Operating Margin
0.21
N/A
N/A
N/A
N/A
-3.7
-0.24
-0.14
N/A
-0.38
Current Valuation
1.9 B
(21.95 M)
406.78 M
(220.97 M)
34.95 M
7.83 B
3.8 B
18.78 B
1.07 B
6.73 B
Price To Book
2.51
0.51
2.47
0.32
1.13
14.55
15.7
5.72
2.38
22.33
Retained Earnings
503.02 M
(594.47 M)
(434.93 M)
(1 B)
(177.63 M)
(2.28 B)
(2.84 B)
(7.96 B)
(574.1 M)
(2.34 B)
Current Asset
214.71 M
144.91 M
N/A
N/A
N/A
125.65 M
115.82 M
106.27 M
22.85 M
170.42 M
Beta
0.9
1.2
1.12
-0.48
1.83
0.65
0.87
0.63
-0.26
0.59
Number Of Employees
58
58
112
224
54
879
702
10.6 K
60
638
Shares Outstanding
18.9 M
61.77 M
70.57 M
292.16 M
56.62 M
59.81 M
124.39 M
97.63 M
69.8 M
63.53 M
Cash Flow From Operations
49.58 M
(78.26 M)
(85.69 M)
(163.69 M)
(58.56 M)
(467.36 M)
(594.74 M)
(1.16 B)
(145.37 M)
(436.85 M)
Total Debt
6.17 M
26.29 M
10.21 M
63.17 M
3.05 M
644.26 M
110.93 M
930.18 M
26.3 M
774.12 M
Return On Equity
0.06
-0.64
-0.46
-0.33
-0.18
-8.18
-1.07
-0.23
-0.36
-0.5
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.013
-0.34
-0.29
-0.19
-0.14
-0.28
-0.16
-0.0958
-0.23
-0.15
Number Of Shares Shorted
900.12 K
3.85 M
11.44 M
12.31 M
2.92 M
3.42 M
21.48 M
1.38 M
3.31 M
5.1 M
Book Value Per Share
44.84
2.03
3.88
2.07
4.46
-2.57
1.94
226.72
10.61
4.93
Current Liabilities
222.82 M
3.09 M
N/A
N/A
N/A
11.45 M
5.13 M
35.17 M
859.05 K
18.64 M
Total Asset
787.22 M
150.54 M
252.01 M
750.03 M
289.64 M
825.59 M
788.73 M
5.81 B
580.27 M
1.05 B
Debt To Equity
0.18
0.11
0.054
0.077
0.011
0.84
0.63
0.12
0.072
0.14
Short Ratio
6.84
6.61
35.88
9.18
13.94
8.5
8.29
3.06
5.52
8.47
Target Price
144.0
8.0
18.73
0.8
7.0
192.85
45.85
280.92
48.27
125.47
Shares Owned By Institutions
98.14
59.68
91.0
58.81
56.43
99.27
97.24
46.9
94.42
99.11
Market Capitalization
2.11 B
37.06 M
676.03 M
168.14 M
286.5 M
7.66 B
3.72 B
20.47 B
1.75 B
6.99 B
Price To Earning
29.74
N/A
N/A
3.66
N/A
-9.1
-6.94
-16.19
-7.43
7.93
Price To Earnings To Growth
1.53
N/A
N/A
0.68
N/A
10.25
-0.3
N/A
0.93
N/A
Price To Sales
13.87
N/A
N/A
2668.88
22642.01
24.13
5.21
0.87
N/A
16.09
Net Income
52.15 M
(102.06 M)
(100.7 M)
(234.63 M)
(66.86 M)
(481.45 M)
(528.63 M)
(881.71 M)
(151.76 M)
(506.98 M)
Earnings Per Share
2.5
-1.17
-1.82
-0.79
-0.85
-7.69
-2.03
-8.18
-3.78
-2.09
Shares Owned By Insiders
1.86
0.49
9.0
13.43
36.44
0.73
13.9
19.43
5.58
0.89
Revenue
131.31 M
N/A
N/A
130 K
N/A
266.72 M
396.59 M
2.46 B
N/A
249.38 M
Working Capital
220.65 M
101.62 M
192.14 M
520.17 M
274.96 M
505.38 M
518.74 M
2.39 B
540.83 M
593.47 M
Cash And Equivalents
147.94 M
239.25 M
227.06 M
655.56 M
359.38 M
955.15 M
852.8 M
5.7 B
180.72 M
853.11 M
Cash Per Share
8.76
4.39
5.74
2.64
6.45
17.11
7.76
55.17
4.81
14.28
Gross Profit
120.06 M
N/A
N/A
63 K
(43.2 M)
271.75 M
297.94 M
(511.06 M)
N/A
421.48 M
Day Typical Price
111.98
0.61
9.78
0.58
4.97
129.7
29.97
185.35
24.94
108.35
Accumulation Distribution
0.0202
0.0635
0.0618
0.0667
0.0874
0.0433
0.0244
0.0187
0.0616
0.0503
Market Facilitation Index
2.29
0.04
0.63
0.04
0.45
5.78
0.74
3.51
1.58
5.55
Daily Balance Of Power
0.3537
0.25
(0.73)
0.5
0.7111
(0.60)
0.2838
0.2023
0.7152
1.099099
Period Momentum Indicator
0.81
0.01
(0.46)
0.02
0.32
(3.49)
0.21
0.71
1.13
6.1
Rate Of Daily Change
1.01
1.02
0.95
1.04
1.07
0.97
1.01
1.0
1.05
1.06
Day Median Price
112.03
0.61
9.89
0.58
4.93
130.49
29.98
185.67
24.84
107.51
Price Action Indicator
0.27
(0.01)
(0.53)
0.01
0.29
(4.11)
0.065
(0.60)
0.87
5.59
Coefficient Of Variation
2445.57
1861.54
1803.47
(749.39)
194335.23
20938.37
1872.5
(817.68)
(1,724)
773.41
Mean Deviation
2.23
7.33
3.53
4.71
4.38
1.68
2.59
1.83
2.7
2.14
Jensen Alpha
0.0937
0.6893
0.2589
(0.89)
(0.03)
0.0
0.1766
(0.33)
(0.22)
0.4187
Total Risk Alpha
0.0438
0.3783
0.1444
(1.06)
(0.15)
(0.05)
0.1053
(0.39)
(0.29)
0.3541
Sortino Ratio
0.0267
0.0812
0.0487
N/A
(0)
(0.01)
0.0425
N/A
N/A
0.1579
Downside Variance
13.32
66.48
24.01
N/A
50.32
3.79
17.27
N/A
N/A
6.92
Standard Deviation
3.11
12.88
4.84
6.67
6.07
2.12
3.86
2.62
3.49
3.44
Kurtosis
1.88
14.03
1.48
1.54
1.27
0.0384
6.33
3.46
(0.03)
11.07
Potential Upside
4.47
20.97
8.04
11.63
8.72
3.56
4.63
3.46
5.23
5.87
Treynor Ratio
0.0988
(1.75)
(12.43)
1.97
(0.01)
0.0292
0.1959
45.28
(0.40)
0.5206
Maximum Drawdown
17.92
84.39
22.87
36.92
33.11
9.74
27.73
17.0
16.66
19.12
Variance
9.65
165.79
23.44
44.54
36.9
4.48
14.92
6.87
12.21
11.86
Market Risk Adjusted Performance
0.1088
(1.74)
(12.42)
1.98
0.0038
0.0392
0.2059
45.29
(0.39)
0.5306
Risk Adjusted Performance
0.0415
0.0543
0.0546
(0.10)
0.0091
0.01
0.0525
(0.1)
(0.04)
0.1156
Skewness
0.1429
3.19
0.199
0.4598
(0.52)
0.4892
(0.81)
(0.62)
0.266
2.27
Semi Deviation
3.34
7.04
4.39
N/A
6.27
1.86
3.79
N/A
N/A
2.19
Information Ratio
0.0313
0.0514
0.0493
(0.14)
(0)
(0.01)
0.0457
(0.13)
(0.07)
0.1207
Value At Risk
(5.43)
(11.88)
(6.91)
(10.68)
(11.01)
(3.13)
(4.71)
(4.87)
(5.05)
(3.53)
Expected Short fall
(2.05)
(10.15)
(3.67)
N/A
(4.68)
(1.94)
(2.79)
N/A
N/A
(2.42)
Downside Deviation
3.65
8.15
4.9
N/A
7.09
1.95
4.16
N/A
N/A
2.63
Semi Variance
11.14
49.6
19.23
N/A
39.31
3.45
14.36
N/A
N/A
4.8

Ligand Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Ligand Pharmaceuticals Competition

Ligand Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Ligand Pharmaceuticals in relation to its competition. Ligand Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Ligand Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Ligand Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Ligand Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Ligand Pharmaceuticals position

In addition to having Ligand Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Natural Foods Thematic Idea Now

Natural Foods
Natural Foods Theme
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Ligand Pharmaceuticals is a strong investment it is important to analyze Ligand Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ligand Pharmaceuticals' future performance. For an informed investment choice regarding Ligand Stock, refer to the following important reports:
How To Invest In Ligand
Details
Is Ligand Stock a good investment?
Details
What is Ligand Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Ligand Pharmaceuticals Correlation with its peers.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY